Marinus Pharmaceuticals Inc (MRNS)

11:03 AM

Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace

11:03 AM

Nov 15, 2024

MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St

Nov 15, 2024

Nov 15, 2024

US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace

Nov 14, 2024

Nov 14, 2024

Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks

Nov 14, 2024

Nov 13, 2024

Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks

Nov 13, 2024

Nov 13, 2024

Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India

Nov 13, 2024

Nov 13, 2024

Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times

Nov 13, 2024

Nov 12, 2024

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 12, 2024

Nov 12, 2024

Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com

Nov 12, 2024

Nov 12, 2024

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian

Nov 12, 2024

Nov 12, 2024

Marinus (MRNS) Q3 Revenue Jumps 56%, Faces Setbacks in Clinical Trials | MRNS Stock News - StockTitan

Nov 12, 2024

Nov 01, 2024

Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN

Nov 01, 2024

Oct 29, 2024

Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada

Oct 29, 2024

Oct 28, 2024

Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal

Oct 28, 2024

Oct 28, 2024

Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 27, 2024

Marinus downgraded after setback to late-stage trial - MSN

Oct 27, 2024

Oct 26, 2024

Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN

Oct 26, 2024

Oct 26, 2024

TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN

Oct 26, 2024

Oct 26, 2024

Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN

Oct 26, 2024

Oct 26, 2024

Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal

Oct 26, 2024

Oct 25, 2024

Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN

Oct 25, 2024

Oct 25, 2024

Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks

Oct 25, 2024

Oct 25, 2024

Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha

Oct 25, 2024

Oct 25, 2024

HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat

Oct 25, 2024

Oct 25, 2024

Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices

Oct 25, 2024

Oct 25, 2024

Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues

Oct 25, 2024

Oct 25, 2024

JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN

Oct 25, 2024

Oct 25, 2024

Marinus halts ganaxolone development after trial setback - Investing.com India

Oct 25, 2024

Oct 25, 2024

Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India

Oct 25, 2024

Oct 24, 2024

Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks

Oct 24, 2024

Oct 24, 2024

Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK

Oct 24, 2024

Oct 24, 2024

Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia

Oct 24, 2024

Oct 24, 2024

Truist cuts Marinus Pharma to hold, drops price target - Investing.com

Oct 24, 2024

Oct 24, 2024

Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK

Oct 24, 2024

Oct 24, 2024

Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com

Oct 24, 2024

Oct 24, 2024

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL

Oct 24, 2024

Oct 24, 2024

Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks

Oct 24, 2024

Oct 24, 2024

Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks

Oct 24, 2024

Oct 24, 2024

Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma

Oct 24, 2024

Oct 24, 2024

Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com

Oct 24, 2024

Oct 24, 2024

Marinus hits record low after discontinuing development of rare disease drug - XM

Oct 24, 2024

Oct 24, 2024

Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada

Oct 24, 2024

Oct 24, 2024

Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch

Oct 24, 2024

Oct 24, 2024

Marinus Therapeutics plans layoffs, explores strategic alternatives as shares sink - The Business Journals

Oct 24, 2024